Mirjam C. Boelens

2.0k citations

29 papers · 1.4k indexed · 1 hit paper · h-index 16

Cancer Research top 5%
- Cancer Genomics and Diagnostics 7
Oncology top 10%
- Colorectal Cancer Treatments and Studies 4
- Cancer Cells and Metastasis 4
- HER2/EGFR in Cancer Research 4
- Lung Cancer Research Studies 3
Molecular Biology top 10%
- Glycosylation and Glycoproteins Research 2
Immunology
Immunology and Allergy top 10%
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 12
- Brain Metastases and Treatment 4

Co-authors: Hemant Ishwaran Andy J. Minn Jos Jonkers Yu Qiu Barzin Y. Nabet Joyce M. Slingerland Petra J. ter Brugge Taewon Yoon
Cited by: Cancer Research Oncology Molecular Biology
Journals: Cell (1 paper)Nature Communications (1 paper)Genes & Development (1 paper)
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Mirjam C. Boelens

26 papers receiving 1.4k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Mirjam C. Boelens

Since Specialization

Citations

This map shows the geographic impact of Mirjam C. Boelens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mirjam C. Boelens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mirjam C. Boelens more than expected).

Fields of papers citing papers by Mirjam C. Boelens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mirjam C. Boelens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mirjam C. Boelens. The network helps show where Mirjam C. Boelens may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mirjam C. Boelens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mirjam C. Boelens Line = papers co-authored together Mirjam C. Boelens links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Improving the diagnosis of leptomeningeal metastases by molecular profiling of cell-free DNA from cerebrospinal fluid European Journal of Cancer ·Berit M. H. van Linder,Dieta Brandsma,Els Verhoeven,Lisa Jongejan,Kim Monkhorst,Adrianus J. de Langen,Daan van den Broek,Dick Pluim,Tom van Wezel,Emma van Kessel,Mirjam C. Boelens	2025	1
2	Divergence of DNA tumor mutations in cerebrospinal fluid in metastatic breast cancer patients with leptomeningeal metastases The Breast ·Peter H. Wessels,Sten Cornellisen,Kim Monkhorst,Gabe S. Sonke,Annegien Broeks,Dorothé Linders,Daan van den Broek,Mirjam C. Boelens,Dieta Brandsma	2025	0
3	Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study Neuro-Oncology ·Tijmen J.W.T. van der Wel,Mirjam C. Boelens,M. Jebbink,Sietske A. Smulders,Klaar W Maas,Merel J.A. Luitse,Annette Compter,Robin P B Boltjes,Nik Sol,Kim Monkhorst,Daan van den Broek,Egbert F. Smit,Adrianus J. de Langen,Dieta Brandsma	2024	5
4	Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort Lung Cancer ·Tijmen J.W.T. van der Wel,M. Jebbink,Daan van den Broek,L. Steinbusch,Willemijn S.M.E. Theelen,G. Ruiter,Wieneke A. Buikhuisen,J.A. Burgers,P. Baas,Marrit Vermeulen,Vincent van der Noort,Sayed M.S. Hashemi,Linda J.W. Bosch,Kim Monkhorst,Egbert F. Smit,Mirjam C. Boelens,Adrianus J. de Langen	2024	3
5	Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC JTO Clinical and Research Reports ·M. Jebbink,Adrianus J. de Langen,Kim Monkhorst,Mirjam C. Boelens,Daan van den Broek,Vincent van der Noort,Cornedine J. de Gooijer,M. Mahn,Anthonie J. van der Wekken,Lizza Hendriks,Sayed M.S. Hashemi,Marthe S. Paats,Anne‐Marie C. Dingemans,Egbert F. Smit	2023	19
6	A review on genetic alterations in CNS metastases related to breast cancer treatment. Is there a role for liquid biopsies in CSF? Journal of Neuro-Oncology ·Peter H. Wessels,Mirjam C. Boelens,Kim Monkhorst,Gabe S. Sonke,Daan van den Broek,Dieta Brandsma	2023	3
7	Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics Journal of Molecular Diagnostics ·Paul Roepman,Ewart de Bruijn,Stef van Lieshout,Lieke Schoenmaker,Mirjam C. Boelens,Hendrikus J. Dubbink,Willemina R.R. Geurts-Giele,Floris H. Groenendijk,Manon M. H. Huibers,Mariëtte E.G. Kranendonk,Margaretha G.M. Roemer,Kris G. Samsom,Marloes Steehouwer,Wendy W.J. de Leng,Alexander Hoischen,Bauke Ylstra,Kim Monkhorst,Jacobus J. M. van der Hoeven,Edwin Cuppen	2021	39
8	1740P Track and treat in NSCLC (TATIN) - ctDNA guided treatment of early resistance to second-line osimertinib treatment in patients with EGFR mutation positive (EGFRm) NSCLC Annals of Oncology ·M. Jebbink,Tijmen J.W.T. van der Wel,Daan van den Broek,Mirjam C. Boelens,Kim Monkhorst,G. Ruiter,Sjaak A. Burgers,L. Steinbusch,Paul Baas,Lisanne E A Kastelijn,Ernst E. van der Wall,Margriet Stellingwerf,Egbert F. Smit,Adrianus J. de Langen	2021	1
9	RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer Journal of Thoracic Oncology ·Teodora Radonic,Willemina R.R. Geurts-Giele,Kris G. Samsom,Guido M.J.M. Roemen,Jan H. von der Thüsen,Erik Thunnissen,Isabelle C. Meijssen,Hein F.B.M. Sleddens,Winand N.M. Dinjens,Mirjam C. Boelens,Karin Weijers,Ernst‐Jan M. Speel,Stephen P. Finn,Cathal Ó’Brien,Tom van Wezel,Daniëlle Cohen,Kim Monkhorst,Paul Roepman,H.J. Dubbink	2021	25
10	The force of HER2 – A druggable target in NSCLC? Cancer Treatment Reviews ·M. Jebbink,Adrianus J. de Langen,Mirjam C. Boelens,Kim Monkhorst,Egbert F. Smit	2020	54
11	Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/− binimetinib or alpelisib British Journal of Cancer ·Sanne C.F.A. Huijberts,Mirjam C. Boelens,René Bernards,Frans L. Opdam	2020	25
12	Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β Laboratory Investigation ·Mieke Raap,Malte Gronewold,Henriette Christgen,Silke Glage,Mohamed Bentires‐Alj,Shany Koren,Patrick W.B. Derksen,Mirjam C. Boelens,Jos Jonkers,Ulrich Lehmann,Friedrich Feuerhake,Elna Kuehnle,Oleg Gluz,Ronald Kates,Ulrike Nitz,Nadia Harbeck,Hans Kreipe,Matthias Christgen	2017	24
13	Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland Genes & Development ·Stefano Annunziato,Sjors M. Kas,Micha Nethe,Hatice Yücel,Jessica Del Bravo,Colin E.J. Pritchard,Rahmen Bin Ali,Bas van Gerwen,Bjørn Siteur,Anne Paulien Drenth,Eva Schut,Marieke van de Ven,Mirjam C. Boelens,Sjoerd Klarenbeek,Ivo J. Huijbers,Martine H. van Miltenburg,Jos Jonkers	2016	100
14	Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathwaysbreakdown → Cell ·Mirjam C. Boelens,Tony J. Wu,Barzin Y. Nabet,Bihui Xu,Yu Qiu,Taewon Yoon,Diana J. Azzam,Christina Twyman-Saint Victor,Brianne Z. Wiemann,Hemant Ishwaran,Petra J. ter Brugge,Jos Jonkers,Joyce M. Slingerland,Andy J. Minn	2014	660
15	Signalling pathway for RKIP and Let‐7 regulates and predicts metastatic breast cancer The EMBO Journal ·Jieun Yun,Casey Frankenberger,Wen-Liang Kuo,Mirjam C. Boelens,Eva M. Eves,Nancy Cheng,Han Liang,Wen‐Hsiung Li,Hemant Ishwaran,Andy J. Minn,Marsha Rich Rosner	2011	167
16	A chronic obstructive pulmonary disease related signature in squamous cell lung cancer Lung Cancer ·Mirjam C. Boelens,Adam M Gustafson,Dirkje S. Postma,Klaas Kok,Gerben van der Vries,Pieter van der Vlies,Avrum Spira,Marc E. Lenburg,Marie Geerlings,Hannie Sietsma,Wim Timens,Anke van den Berg,Harry J.M. Groen	2010	24
17	Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis Lung Cancer ·Mirjam C. Boelens,Klaas Kok,Pieter van der Vlies,Gerben van der Vries,Hannie Sietsma,Wim Timens,Dirkje S. Postma,Harry J.M. Groen,Anke van den Berg	2009	54
18	Current smoking‐specific gene expression signature in normal bronchial epithelium is enhanced in squamous cell lung cancer The Journal of Pathology ·Mirjam C. Boelens,Anke van den Berg,Rudolf S.N. Fehrmann,Marie Geerlings,Wouter K. de Jong,Gerard J. te Meerman,Hannie Sietsma,Wim Timens,Dirkje S. Postma,Harry J.M. Groen	2009	51
19	Microarray amplification bias: loss of 30% differentially expressed genes due to long probe – poly(A)-tail distances BMC Genomics ·Mirjam C. Boelens,Gerard J. te Meerman,Johan H. Gibcus,Tjasso Blokzijl,H. Marike Boezen,Wim Timens,Dirkje S. Postma,Harry J.M. Groen,Anke van den Berg	2007	16
20	Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus Journal of Clinical Pathology ·Mirjam C. Boelens,Anke van den Berg,Irma Vogelzang,Jelle Wesseling,Dirkje S. Postma,Wim Timens,Harry J.M. Groen	2006	54

About Mirjam C. Boelens

Mirjam C. Boelens is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 29 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (12 papers), Cancer Genomics and Diagnostics (7 papers), Brain Metastases and Treatment (4 papers), Colorectal Cancer Treatments and Studies (4 papers), Cancer Cells and Metastasis (4 papers), HER2/EGFR in Cancer Research (4 papers), Lung Cancer Research Studies (3 papers) and Glycosylation and Glycoproteins Research (2 papers). The work is most often cited by research in Cancer Research (638 citations), Oncology (447 citations) and Molecular Biology (1.0k citations). Mirjam C. Boelens has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Hemant Ishwaran, Andy J. Minn, Jos Jonkers, Yu Qiu, Barzin Y. Nabet, Joyce M. Slingerland, Petra J. ter Brugge, Taewon Yoon, Bihui Xu and Tony J. Wu. Their work appears in journals such as Cell, Nature Communications and Genes & Development.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact